Logo
x

Search

Subscribe Now

gsk

GSK’s Jemperli Plus Chemotherapy Receives the EC’s Approval as a 1L Treatment of Primary Advanced or Recurrent Endometrial Cancer

GSK’s Jemperli Plus Chemotherapy Receives the EC’s Approval as a 1L Treatment of Primary Advanced or Recurrent Endometrial Cancer

  • January 20, 2025
GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio

GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio

  • January 13, 2025
GSK’s GSK’227 Secures the US FDA’s Breakthrough Therapy Designation for Treating Late-Line R/R Osteosarcoma

GSK’s GSK’227 Secures the US FDA’s Breakthrough Therapy Designation for Treating Late-Line R/R Osteosarcoma

  • January 7, 2025
GSK’s Nucala (Mepolizumab) Secures the NMPA’s Approval for Treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

GSK’s Nucala (Mepolizumab) Secures the NMPA’s Approval for Treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

  • January 3, 2025
GSK Reports the Data from the P-III (FIRST-ENGOT-OV44) Study Evaluating Zejula and Jemperli in 1L Advanced Ovarian Cancer

GSK Reports the Data from the P-III (FIRST-ENGOT-OV44) Study Evaluating Zejula and Jemperli in 1L Advanced Ovarian Cancer

  • December 20, 2024
GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer

GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer

  • December 19, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.